Onco-Innovations Limited
CBOE CATotal Valuation
Onco-Innovations Limited carries a market capitalization of 38.72M, placing it among publicly traded companies globally.
| Market Cap | 38.72M |
| Enterprise Value | N/A |
Share Statistics
Onco-Innovations Limited currently has 57.55M shares outstanding.
| Shares Outstanding | 57.55M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 369.59, and the price-to-book ratio stands at -43.41.
| PE Ratio | N/A |
| PS Ratio | 369.59 |
| PB Ratio | -43.41 |
| P/TBV Ratio | 147.03 |
| P/FCF Ratio | -10.39 |
| P/OCF Ratio | -10.39 |
Financial Position
Onco-Innovations Limited maintains a current ratio of 1.87, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.87 |
| Quick Ratio | 1.23 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -3,099.37 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Onco-Innovations Limited's stock has declined approximately -68.29268% over the past 52 weeks. The 50-day moving average sits at 0.84, while the 200-day moving average is 1.08.
| Beta (5Y) | N/A |
| 52-Week Price Change | -68.29268% |
| 50-Day Moving Average | 0.84 |
| 200-Day Moving Average | 1.08 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Onco-Innovations Limited generated 154,669.00 in revenue and converted that into -14.89M in net income, yielding earnings per share of -0.27. EBITDA reached -11.22M, while operating income came in at -11.22M.
| Revenue | 154,669.00 |
| Gross Profit | N/A |
| Operating Income | -11.22M |
| Pretax Income | -14.89M |
| Net Income | -14.89M |
| EBITDA | -11.22M |
| EBIT | -11.22M |
| Earnings Per Share (EPS) | -0.27 |
Balance Sheet
Total book value stands at -1.32M, with working capital of 388,797.00 providing operational flexibility.
| Cash & Cash Equivalents | 514,038.00 |
| Total Debt | N/A |
| Net Debt | -514,038.00 |
| Equity (Book Value) | -1.32M |
| Book Value Per Share | -0.02 |
| Working Capital | 388,797.00 |
Cash Flow
Onco-Innovations Limited produced -5.50M in operating cash flow over the past twelve months.
| Operating Cash Flow | -5.50M |
| Capital Expenditures | N/A |
| Free Cash Flow | -5.50M |
| FCF Per Share | -0.10 |
Margins
Onco-Innovations Limited operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -7,255.60 and net profit margin of -9,624.73 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -7,255.60 |
| Pretax Margin | -9,624.73 |
| Profit Margin | -9,624.73 |
| EBITDA Margin | -7,255.60 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -8.04 |
| FCF Yield | -9.62 |
Scores
Onco-Innovations Limited posts an Altman Z-Score of 4.84, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.84 |